The credit facility for Davita was expected to be wrapped up last week and allocate toward the end of this month. The final terms on the JPMorgan-led facility are expected to be a $250 million revolver priced at LIBOR plus 2%, a $250 million term loan "A" priced at LIBOR plus 2% and a $2.65 billion term loan "B" priced at LIBOR plus 2 1/4%. Price talk on the "B" has been between LIBOR plus 2 1/4% and LIBOR plus 2 1/2%.
The pricing was increased from its launch date in early May with original terms of LIBOR plus 1 3/4% on the revolver and "A" loan and LIBOR plus 2% on the "B" loan.
The loan will back the company's $3.05 billion acquisition of Gambro Healthcare. The deal was first announced in early December. Davita provides dialysis services to patients suffering from kidney failure. The transaction will add about 565 dialysis centers to Davita's operations. The combined company will serve about 96 thousand patients in 21 states and Washington, D.C. A spokeswoman from Davita could not be reached before press time.